SequelSEC

GALECTIN THERAPEUTICS INC GALT

Pharmaceutical Preparations · CIK 0001133416 · Fiscal year ends 1231

Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$15.62M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

GALECTIN THERAPEUTICS INC (GALT) reported net income of -$27.84M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from GALECTIN THERAPEUTICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

GALECTIN THERAPEUTICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$15.62M
Net income-$27.84M
Research & development$8.91M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$6.71M
Selling & marketingUnavailable

Balance

GALECTIN THERAPEUTICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$13.27M
Total assets$14.83M
Current assets$14.66M
Total liabilities$151.68M
Current liabilities$151.62M
Total equity incl. NCI-$138.58M
Temporary (mezzanine) equity$1.72M
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.73M

Cash flow

GALECTIN THERAPEUTICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$15.89M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$15.39M
Net change in cashUnavailable
Stock-based compensation$2.34M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

GALECTIN THERAPEUTICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.10x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GALT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.